Sarah Cannon
June 01, 2016

NASHVILLE, TENN., June 1, 2016 – Sarah Cannon announce the promotion of Erika P. Hamilton, MD, to director, breast and gynecologic cancer research program. Over the past three years, Hamilton has been instrumental in the growth and success of the breast and gynecologic cancer research program at Sarah Cannon.

“Erika has quickly become a recognized thought leader in the field of women’s cancer research by not only her research peers, but also the pharmaceutical and biotech industry for her contributions to drug development,” said Howard A. “Skip” Burris, MD, chief medical officer for Sarah Cannon. “Focused on ensuring patients have the best care from diagnosis through survivorship, Erika is dedicated to bringing forward new treatment options and diagnostics that are helping to transform how we identify and treat a variety of breast and gynecological cancers.”

Hamilton’s research focuses on novel therapies, personalized medicine and immunotherapy. Hamilton will continue to care for patients at Sarah Cannon Research Institute in Nashville, Tenn. and is an associate with Tennessee Oncology, PLLC.

She received her undergraduate degree from Washington and Lee University in Virginia and completed her medical degree and residency from University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University and is board certified in internal medicine and oncology.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute is the research arm of HCA’s global cancer institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. Sarah Cannon’s network of strategic sites includes more than 275 physicians who engage in research. The organization has led more than 220 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in more than two-thirds of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations (formerly known as SCRI Development Innovations). For more information, visit